ALX Oncology posts Q2 2026 results, reaffirms mid-2027 ASPEN-09-Breast readout
The company also detailed new HER2-positive breast cancer data, an on-track ALX2004 safety readout, and $153.4 million in cash.
SEC filing
Latest
1 story
Sign inSign in1 story
The company also detailed new HER2-positive breast cancer data, an on-track ALX2004 safety readout, and $153.4 million in cash.
SEC filing